Cargando…
Arterial hypertension – Clinical trials update 2021
AIM: This review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. DATA SYNTHESIS: The trials included in this review are related to hypertension onset age and risk for future cardiovascular...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444354/ https://www.ncbi.nlm.nih.gov/pubmed/34690044 http://dx.doi.org/10.1016/j.numecd.2021.09.007 |
_version_ | 1784568474190741504 |
---|---|
author | Al Ghorani, Hussam Götzinger, Felix Böhm, Michael Mahfoud, Felix |
author_facet | Al Ghorani, Hussam Götzinger, Felix Böhm, Michael Mahfoud, Felix |
author_sort | Al Ghorani, Hussam |
collection | PubMed |
description | AIM: This review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. DATA SYNTHESIS: The trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, and the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension. CONCLUSIONS: Hypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension. |
format | Online Article Text |
id | pubmed-8444354 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84443542021-09-16 Arterial hypertension – Clinical trials update 2021 Al Ghorani, Hussam Götzinger, Felix Böhm, Michael Mahfoud, Felix Nutr Metab Cardiovasc Dis Review AIM: This review aims to summarize and discuss some of the most relevant clinical trials in epidemiology, diagnostics, and treatment of hypertension published in 2020 and 2021. DATA SYNTHESIS: The trials included in this review are related to hypertension onset age and risk for future cardiovascular disease, reliability of different blood pressure monitoring methods, role of exercise-induced hypertension, treatment of hypertension in patients with SARS-CoV-2 infection, management of hypertension high-risk patient groups, e.g., in the elderly (≥80 years) and patients with atrial fibrillation, and the interplay between nutrition and hypertension, as well as recent insights into renal denervation for treatment of hypertension. CONCLUSIONS: Hypertension onset age, nighttime blood pressure levels and a riser pattern are relevant for the prognosis of future cardiovascular diseases. The risk of coronary heart disease appears to increase linearly with increasing exercise systolic blood pressure. Renin-angiotensin system blockers are not associated with an increased risk for a severe course of COVID-19. In elderly patients, a risk-benefit assessment of intensified blood pressure control should be individually evaluated. A J-shaped association between cardiovascular disease and achieved blood pressure could also be demonstrated in patients with atrial fibrillation on anticoagulation. Salt restriction and lifestyle modification remain effective options in treating hypertensive patients at low cardiovascular risk. Sodium glucose co-transporter 2 inhibitors and Glucagon-like peptide-1 receptor agonists show BP-lowering effects. Renal denervation should be considered as an additional or alternative treatment option in selected patients with uncontrolled hypertension. The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. 2022-01 2021-09-16 /pmc/articles/PMC8444354/ /pubmed/34690044 http://dx.doi.org/10.1016/j.numecd.2021.09.007 Text en © 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Review Al Ghorani, Hussam Götzinger, Felix Böhm, Michael Mahfoud, Felix Arterial hypertension – Clinical trials update 2021 |
title | Arterial hypertension – Clinical trials update 2021 |
title_full | Arterial hypertension – Clinical trials update 2021 |
title_fullStr | Arterial hypertension – Clinical trials update 2021 |
title_full_unstemmed | Arterial hypertension – Clinical trials update 2021 |
title_short | Arterial hypertension – Clinical trials update 2021 |
title_sort | arterial hypertension – clinical trials update 2021 |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8444354/ https://www.ncbi.nlm.nih.gov/pubmed/34690044 http://dx.doi.org/10.1016/j.numecd.2021.09.007 |
work_keys_str_mv | AT alghoranihussam arterialhypertensionclinicaltrialsupdate2021 AT gotzingerfelix arterialhypertensionclinicaltrialsupdate2021 AT bohmmichael arterialhypertensionclinicaltrialsupdate2021 AT mahfoudfelix arterialhypertensionclinicaltrialsupdate2021 |